

Summary statistics - qualitative results

(Groups: measurement principle)

EQA round: AIH1/22 - Autoimmune Liver Diseases

Deadline: 11.03.2022

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group	N	Result	N _{rel}
(451) AMA				
A	(1) Fluorescent methods	>>> 51	Positive	100 %
Total per sample: n = 51		Success: 100 %		
B	(1) Fluorescent methods	1	Negative	2,0 %
		1	Inconclusive result (borderline)	2,0 %
		>>> 49	Positive	96 %
Total per sample: n = 51		Success: 96 %		
Total success: 96 %				
(456) AMA-M2				
A	(2) EIA methods	>>> 12	Positive	19 %
	(5) Immunoblotting	>>> 50	Positive	81 %
Total per sample: n = 62		Success: 100 %		
B	(2) EIA methods	>>> 12	Positive	19 %
	(5) Immunoblotting	>>> 50	Positive	81 %
Total per sample: n = 62		Success: 100 %		
Total success: 100 %				
(454) anti-gp210				
A	(0) Not specified	1	Negative	2,0 %
	(2) EIA methods	>>> 1	Positive	2,0 %
	(5) Immunoblotting	>>> 47	Positive	96 %
Total per sample: n = 49		Success: 98 %		
B	(0) Not specified	>>> 1	Negative	2,0 %
	(2) EIA methods	>>> 1	Negative	2,0 %
	(5) Immunoblotting	>>> 43	Negative	88 %
		3	Inconclusive result (borderline)	6,1 %
		1	Positive	2,0 %
Total per sample: n = 49		Success: 92 %		
Total success: 90 %				
(457) anti-LC-1				
A	(2) EIA methods	>>> 4	Negative	6,9 %
	(5) Immunoblotting	>>> 54	Negative	93 %
Total per sample: n = 58		Success: 100 %		
B	(2) EIA methods	>>> 4	Negative	6,9 %
	(5) Immunoblotting	>>> 52	Negative	90 %
		2	Inconclusive result (borderline)	3,4 %
Total per sample: n = 58		Success: 97 %		
Total success: 97 %				
(452) anti-LKM				
A	(1) Fluorescent methods	>>> 44	Negative	96 %
		1	Positive	2,2 %
	(5) Immunoblotting	>>> 1	Negative	2,2 %
Total per sample: n = 46		Success: 98 %		
B	(1) Fluorescent methods	>>> 45	Negative	98 %
	(5) Immunoblotting	>>> 1	Negative	2,2 %
Total per sample: n = 46		Success: 100 %		
Total success: 98 %				
(455) anti-LKM1				
A	(2) EIA methods	>>> 13	Negative	21 %
	(5) Immunoblotting	>>> 49	Negative	79 %
Total per sample: n = 62		Success: 100 %		
B	(2) EIA methods	>>> 13	Negative	21 %
	(5) Immunoblotting	>>> 49	Negative	79 %
Total per sample: n = 62		Success: 100 %		
Total success: 100 %				
(458) anti-SLA				
A	(2) EIA methods	>>> 8	Negative	13 %
	(5) Immunoblotting	>>> 52	Negative	87 %
Total per sample: n = 60		Success: 100 %		
B	(2) EIA methods	>>> 8	Negative	13 %
	(5) Immunoblotting	>>> 52	Negative	87 %
Total per sample: n = 60		Success: 100 %		
Total success: 100 %				

Summary statistics - qualitative results

(Groups: measurement principle)

EQA round: AIH1/22 - Autoimmune Liver Diseases

Deadline: 11.03.2022

Test			N	Result	N _{rel}
Sample	Group				
(459) anti-sp100					
A	(2) EIA methods	>>>	1	Negative	2,1 %
	(5) Immunoblotting	>>>	41	Negative	85 %
			4	Inconclusive result (borderline)	8,3 %
			2	Positive	4,2 %
----- Total per sample: n = 48 -----		Success: 88 %	-----		
B	(2) EIA methods	>>>	1	Negative	2,1 %
	(5) Immunoblotting	>>>	40	Negative	83 %
			3	Inconclusive result (borderline)	6,3 %
			4	Positive	8,3 %
----- Total per sample: n = 48 -----		Success: 85 %	-----		
Total success: 83 %					

(453) SMA					
A	(1) Fluorescent methods	>>>	51	Negative	98 %
	(5) Immunoblotting	>>>	1	Negative	1,9 %
----- Total per sample: n = 52 -----		Success: 100 %	-----		
B	(1) Fluorescent methods	>>>	51	Negative	98 %
	(5) Immunoblotting	>>>	1	Negative	1,9 %
----- Total per sample: n = 52 -----		Success: 100 %	-----		
Total success: 100 %					

st_kl

End of report

Printed: 21.03.2022